Bromo-DragonFLY is a difuran analog of the Schedule I hallucinogen 4-bromo-2,5-dimethoxyphenethylamine. This designer drug strongly binds serotonin receptors (Ki = 0.04, 0.19, and 0.02 nM for 5-HT2A, 5-HT2B, and 5-HT2C, respectively). It is more potent than LSD in drug discrimination studies in rats. Related to its high potency, Bromo-DragonFLY has been associated with fatalities as well as acute intoxications. GC-MS, GC-IRD, and solid phase FTIR spectra have been published. This product is intended for research and forensic purposes.
